EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Tocilizumab-Based Treatment of Microvascular Inflammation in Kidney Transplant Recipients: A Retrospective Study

Johan Noble, Giorgia Comai, Valeria Corredetti, Reda Laamech, Celine Dard, Thomas Jouve, Diane Giovannini, Audrey Le Gouellec, Shivani Wadnerkar, Paolo Cravedi, Della Apuzzo, Daniele Vetrano und 5 weitere

Transplant International · 16.05.2025 · 38

DOI: 10.3389/ti.2025.14502 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Transplant International, online erschienen am 16.05.2025. Verfasst von Johan Noble und 16 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, University hospital Grenoble, Grenoble, France. Hauptthemen laut MEDLINE: Kidney Transplantation, Antibodies, Monoclonal, Humanized, Graft Rejection, Inflammation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic-active antibody mediated rejection (caAMR) is the leading causes of long-term kidney graft failure. Tocilizumab (TCZ), an anti-IL-6 receptor antibody, has been suggested as a treatment, but data are conflicting. We retrospectively studied consecutive adult kidney transplant recipients with caAMR or microvascular inflammation (MVI) without Donor-Specific Antibodies (DSA) and without C4d deposition (MVI + DSA-C4d-), who received TCZ as first-line therapy in two European centers. Estimated glomerular filtration rate (eGFR) and DSA were assessed one-year before and after TCZ initiation. The study included 64 patients who received TCZ between July 2018 and September 2023. The eGFR trajectory significantly decreased after TCZ treatment (−1.2 ± 0.2 vs. 0.03 ± 0.2 mL/min/1.73 m 2 /month pre- vs. post-TCZ, respectively; p = 0.001). The percentage of patients with DSA decreased from 63.9% to 38.9% (p < 0.001), and the average MFI decreased from 9,537 to 7,250 (p = 0.001). In multivariate analysis, younger age (OR = 0.95, p = 0.02), MVI + DSA-C4d- phenotype (OR = 5.2, p = 0.01), and lower chronic glomerulopathy score (OR = 4.5, p = 0.02) were associated with TCZ response (trajectory ≥0 after TCZ). Patient survival was 98.4%, and graft survival was 93.7% at one-year. First-line TCZ therapy for caAMR or MVI + DSA-C4d- is associated with an improvement of eGFR trajectories, reduced DSA numbers and MFI and histological inflammation in glomeruli. These data suggest a potential benefit of TCZ in these settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationAntibodies, Monoclonal, HumanizedGraft RejectionInflammationHumansRetrospective StudiesMaleFemaleMiddle AgedAdultGlomerular Filtration RateAgedMicrovesselsGraft Survival

Stichwörter der Autor:innen

chronic-active antibody-mediated rejectiondonor-specific antibodykidney transplantationmicrovascular inflammationtocilizumab

Substanzen

Antibodies, Monoclonal, Humanizedtocilizumab

Autor:innen und Institutionen

  • Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, University hospital Grenoble, Grenoble, France.
  • Univ. Grenoble Alpes, CNRS, Inserm, U 1209 CNRS UMR 5309, Team Epigenetis Immunity, Metabolism, Cell Signaling and Cancer, Institute for advanced Biosciences, Grenoble, France.
  • Precision Immunology Institute, Translational Transplant Research Center (TTRC), Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Nephrology, Dialysis and Kidney Transplant Unit, IRCCS-Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-University of Bologna, Bologna, Italy.
  • Établissement Français du Sang Auvergne-Rhône-Alpes, HLA and immunogenetics Laboratory, Grenoble, France.

Zitieren

APA

Noble, J., Comai, G., Corredetti, V., Laamech, R., Dard, C., Jouve, T., Giovannini, D., Le Gouellec, A., Wadnerkar, S., Cravedi, P., Apuzzo, D., Vetrano, D., Busutti, M., Abenavoli, C., Malvezzi, P., Rostaing, L. P., & Lamanna, G. (2025). Tocilizumab-Based Treatment of Microvascular Inflammation in Kidney Transplant Recipients: A Retrospective Study. Transplant International, 38. https://doi.org/10.3389/ti.2025.14502

Vancouver

Noble J, Comai G, Corredetti V, Laamech R, Dard C, Jouve T, et al. Tocilizumab-Based Treatment of Microvascular Inflammation in Kidney Transplant Recipients: A Retrospective Study. Transplant International. 2025;38. doi:10.3389/ti.2025.14502

BibTeX
@article{Noble2025,
  author = {Noble, Johan and Comai, Giorgia and Corredetti, Valeria and Laamech, Reda and Dard, Celine and Jouve, Thomas and Giovannini, Diane and Le Gouellec, Audrey and Wadnerkar, Shivani and Cravedi, Paolo and Apuzzo, Della and Vetrano, Daniele and Busutti, Marco and Abenavoli, Chiara and Malvezzi, Paolo and Rostaing, Lionel Pe and Lamanna, Gaetano},
  title = {Tocilizumab-Based Treatment of Microvascular Inflammation in Kidney Transplant Recipients: A Retrospective Study},
  journal = {Transplant International},
  year = {2025},
  volume = {38},
  doi = {10.3389/ti.2025.14502}
}
Kostenlos starten →